Skip to main content

FCPM III Services B.V.

SEC CIK
0002013410
Latest filing
Aug 14, 2026

The latest 13F from FCPM III Services B.V. covers Q2 2026 (filed Aug 14, 2026): 11 long positions worth $750.4M. The top 10 holdings make up 99.9% of the portfolio, and the largest is NewAmsterdam Pharma Co N.V. (NAMS) at 38.3%. Livermore has 11 filings on Form 13F from this institution, going back to Q4 2023.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
1
Est. +$28.8M
Added
0
Reduced
2
Est. −$41.7M
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. NAMSNewAmsterdam Pharma Co N.V.
    38.3%$287.7MHistory
  2. MPLTMapLight Therapeutics, Inc.
    15.4%$115.6MHistory
  3. DYNDyne Therapeutics, Inc.
    11.4%$85.5MHistory
  4. VORVor Biopharma Inc.
    10.1%$75.8MHistory
  5. DMRADamora Therapeutics, Inc.
    8.5%$63.5MHistory

Share of portfolio

Top 5 holdings and the other 6 positions, by share of portfolio value

  1. NAMS38.3%
  2. MPLT15.4%
  3. DYN11.4%
  4. VOR10.1%
  5. DMRA8.5%
  6. Other 6 positions16.3%

Biggest buys

New and added positions, by estimated amount bought

  1. AURAAura Biosciences, Inc.
    +$28.8MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AURAAura Biosciences, Inc.
    +3.84 pp0.0% → 3.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. NAMSNewAmsterdam Pharma Co N.V.
    −$24.0MReducedHistory
  2. DYNDyne Therapeutics, Inc.
    −$17.7MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. NAMSNewAmsterdam Pharma Co N.V.
    −2.43 pp40.8% → 38.3%History
  2. DYNDyne Therapeutics, Inc.
    −0.27 pp11.7% → 11.4%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$750.4M
+$28.2M (+3.9%) vs. prior quarter
Positions
11
+1 vs. prior quarter
Top 10 concentration
99.9%
Top 10 as share of value
Turnover
3.9%
Q2 2026, one quarter
Average holding period
7.6 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2023), so positions held before then are understated.

13F filings by quarter

11 quarters, going back to Q4 2023. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $762.9M (Q4 2025)

Q4 2023: $339.4MQ1 2024: $707.3MQ2 2024: $678.1MQ3 2024: $582.3MQ4 2024: $592.4MQ1 2025: $413.7MQ2 2025: $369.2MQ3 2025: $500.4MQ4 2025: $762.9MQ1 2026: $722.2MQ2 2026: $750.4M
Q4 2023Q2 2026
13F filings of FCPM III Services B.V. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202611$750.4MNAMSMPLTDYNvs. Q1 2026SEC
Q1 2026May 15, 202610$722.2MNAMSDYNVORvs. Q4 2025SEC
Q4 2025Feb 17, 202610$762.9MNAMSDYNENGNvs. Q3 2025SEC
Q3 2025Nov 14, 20259$500.4MNAMSDYNENGNvs. Q2 2025SEC
Q2 2025Aug 14, 20258$369.2MNAMSDYNREPLvs. Q1 2025SEC
Q1 2025May 15, 20257$413.7MNAMSDYNENGNvs. Q4 2024SEC
Q4 2024Feb 14, 20258$592.4MNAMSDYNENGNvs. Q3 2024SEC
Q3 2024Nov 14, 20247$582.3MDYNNAMSENGNvs. Q2 2024SEC
Q2 2024Aug 8, 20247$678.1MDYNNAMSENGNvs. Q1 2024SEC
Q1 2024May 3, 20246$707.3MNAMSDYNENGNvs. Q4 2023SEC
Q4 2023Mar 7, 20246$339.4MNAMSDYNENGN–SEC